Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Clinical trial NCT06598306 · RECRUITING

Trial details

NCT number: NCT06598306
Sponsor: Amgen
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Extensive Stage Small Cell Lung Cancer

Start date: 2024-10-07
Primary completion: 2027-04-24
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.